Literature DB >> 1682642

Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia.

J Gmür1, J Burger, U Schanz, J Fehr, A Schaffner.   

Abstract

Early studies suggested that the risk of haemorrhagic complications become unacceptable when platelet counts drop below 20 x 10(9)/l. Because there are insufficient data to define 20 x 10(9)/l as the threshold for prophylactic platelet transfusions, the practicability of a more restrictive transfusion policy has been assessed prospectively in 102 consecutive patients being treated for acute leukaemia. Besides platelet count, the transfusion protocol took into consideration factors such as presence of bleeding, fever, coagulation disorders, and intention to do therapeutic procedures. 31 major bleeding episodes occurred on 1.9% of the study days when platelet counts were 10 x 10(9)/l or less and on 0.07% of study days when counts were 10-20 x 10(9)/l. The findings indicate that the threshold for prophylactic transfusions can safely be set at 5 x 10(9)/l in patients without fever or bleeding manifestations and at 10 x 10(9)/l in patients with such signs. For patients with coagulation disorders or anatomical lesions, or for those on heparin, the threshold should be at least 20 x 10(9)/l. Such a restrictive platelet transfusion policy, which is applicable not only to thrombocytopenia associated with acute leukaemia but also to other forms of hypoproliferative thrombocytopenia, reduces exposure of such patients to blood donors and results in substantial health-care savings.

Entities:  

Mesh:

Year:  1991        PMID: 1682642     DOI: 10.1016/0140-6736(91)92098-m

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

1.  Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation.

Authors:  Martin David Berger; Bernhard Gerber; Kornelius Arn; Oliver Senn; Urs Schanz; Georg Stussi
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

Review 2.  Recommendations for the transfusion of plasma and platelets.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

3.  Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation.

Authors:  Lise J Estcourt; Simon Stanworth; Carolyn Doree; Marialena Trivella; Sally Hopewell; Michael F Murphy; Alan Tinmouth
Journal:  Cochrane Database Syst Rev       Date:  2014

4.  Flow cytometry and thromboelastography to assess platelet counts and coagulation in patients with haematological malignancies.

Authors:  Alex Gatt; Fabian Bonello; Raphael Buttigieg; Samuel Debono; Patricia Brincat; Charlie Grima; Peter Gatt; Thomas Lofaro; Stefan Laspina
Journal:  Blood Transfus       Date:  2014-06-05       Impact factor: 3.443

5.  Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party.

Authors:  Giuseppe Tagariello; Giancarlo Castaman; Anna Falanga; Rita Santoro; Mariasanta Napolitano; Sergio Storti; Dino Veneri; Marco Basso; Laura Candiotto; Cristina Tassinari; Augusto B Federici; Valerio De Stefano
Journal:  Blood Transfus       Date:  2016-06-24       Impact factor: 3.443

6.  Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders.

Authors:  Asma Ashraf; Andreas V Hadjinicolaou; Carolyn Doree; Sally Hopewell; Marialena Trivella; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01

7.  Bleeding frequency and characteristics among hematologic malignancy inpatient rehabilitation patients with severe thrombocytopenia.

Authors:  Jack B Fu; Jegy M Tennison; Isabel M Rutzen-Lopez; Julie K Silver; Shinichiro Morishita; Seyedeh S Dibaj; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2018-03-28       Impact factor: 3.603

8.  Hyperthermia inhibits platelet hemostatic functions and selectively regulates the release of alpha-granule proteins.

Authors:  J Etulain; M J Lapponi; S J Patrucchi; M A Romaniuk; R Benzadón; G L Klement; S Negrotto; M Schattner
Journal:  J Thromb Haemost       Date:  2011-08       Impact factor: 5.824

Review 9.  Component therapy.

Authors:  K M Radhakrishnan; Srikumar Chakravarthi; S Pushkala; J Jayaraju
Journal:  Indian J Pediatr       Date:  2003-08       Impact factor: 1.967

10.  Factors associated with transfusion requirements during treatment for acute myelogenous leukemia.

Authors:  G Favre; M Fopp; J Gmür; A Tichelli; M F Fey; A Tobler; E Schatzmann; A Gratwohl
Journal:  Ann Hematol       Date:  1993-10       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.